News_News_Lynk Pharmaceutical (Hangzhou) Co., Ltd.

+86 0571-87711179

ychen1@lynkpharma.com

Lynk Pharmaceuticals Co., Ltd. | 浙ICP备19010130号-2 | Powered by www.300.cn | Manager

CONTACT US

website

ABOUT US

Company

Leadership

Scientific Advisory Board

291 Fucheng Road, Bldg 5-402, Jianggan, Hangzhou,
Zhejiang 310018, China

Home page

News

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

2021-08-27 14:33

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002

2021-08-12 15:20

Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002

Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003

2021-06-25 20:16

Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003

Lynk Pharmaceuticals Appoints Dr. Wang Weigand as Chief Medical Officer

2021-01-20 15:21

Lynk Pharmaceuticals enters exclusive licensing agreements develop RAS inhibitors with a novel MOA

2020-07-28 11:51

HANGZHOU, China, July 27, 2020 /PRNewswire/ -- Lynk Pharmaceuticals is pleased to announce exclusive licensing agreements with Kobe
University and RIKEN Research Institute to develop RAS inhibitors with a novel MOA.

Lynk Pharmaceuticals successfully out-licensed a preclinical candidate

2020-07-19 16:59

Lynk Pharmaceuticals successfully out-licensed a preclinical candidate to a US company in April, 2020. Details will be announced at a later date.